Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | PRNP | P04156 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LTB4R | Q15722 | 5/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5560898 | 0.77 | RXFP1 (0.49) | RXFP1ALDH1A1LMNAPRNPRECQL | |
| SCHEMBL5567118 | 0.77 | ALDH1A1 (0.38) | RXFP1ALDH1A1LMNAPRNPRECQL | |
| SCHEMBL5561516 | 0.75 | RXFP1 (0.47) | RXFP1ALDH1A1LMNAPRNPRECQL | |
| SCHEMBL2179325 | 0.74 | RXFP1 (0.66) | RXFP1ALDH1A1LMNAPRNPRECQL | |
| SCHEMBL10648666 | 0.69 | TDP1 (0.54) | RXFP1ALDH1A1LMNAPRNPRECQL | |
| SCHEMBL15908887 | 0.68 | MAPT (0.56) | RXFP1MAPTLTB4RRXRANR1H2 | |
| SCHEMBL8419778 | 0.68 | HPGD (0.50) | RXFP1ALDH1A1LMNAPRNPRECQL | |
| SCHEMBL432295 | 0.67 | RXFP1 (0.62) | RXFP1ALDH1A1LMNAPRNPRECQL | |
| Methylamine SCHEMBL8360182 | 0.66 | TSHR (0.48) | ALDH1A1LMNARECQLTDP1 | |
| SCHEMBL1573827 | 0.66 | CTSS (0.42) | ALDH1A1TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240161-B1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-6762190-B2 | VITRONECTIN RECEPTOR ANTAGONISTS; SUPPRESSING OSTEOCLAST BONE RESORPTION; PREVENTING ANGIOGENESIS OR VASCULAR SMOOTH MUSCLE PROLIFERATION | AVENTIS PHARMA S.A. DEUTSCHLAND GMBH GENENTECH, INC. (DE) | 2004-07-13 | — | — | US | disclosed |
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | AVENTIS PHARMA S.A. DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1240161-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044237-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
| EP-1108721-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | VCAM1, TEK, ADGRF1 | RXFP1 27/4885ALDH1A1 2525/4885LMNA 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.